Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
|Videos|January 24, 2020
Managing A Case of Heavily Pretreated Recurrent Ovarian Cancer
Managing A Case of Heavily Pretreated Recurrent Ovarian Cancer
Advertisement
Case: A 58-Year-Old Female With Heavily Pretreated Recurrent Ovarian Cancer
H & P
- 58-year-old female diagnosed in 2014 with stage IV ovarian cancer
- Pathology: high-grade serous carcinoma, epithelial ovarian cancer
- CA-125: 460 U/mL
- CT with contrast of the pelvis, abdomen, and chest revealed a 4-cm mass in the left ovary and peritoneal carcinomatosis
- Patient underwent suboptimal debulking surgery; residual disease 1.5 cm
- Received IV/IP carboplatin/paclitaxel (6 cycles); achieved complete remission
- 2 years later (2016) symptoms returned; CA 125, 255 U/mL; ECOG: 1
- Received carboplatin/paclitaxel (6 cycles) and bevacizumab; achieved good partial remission; CA 125, 45 U/mL; continued on bevacizumab maintenance
- 1.5-years following second-line therapy (2017), again presented with symptoms; CA 125, 550 U/mL; ECOG: 0
- Genetic testing;gBRCA1/2wild-type
- Received carboplatin/gemcitabine (6 cycles); CA 125, 46 U/mL; achieved complete remission
- Currently:
- CA 125, 620 U/mL
- CT shows several small masses in the lung left lower lobe (largest is 3 cm)
- ECOG: 0
Advertisement
Related to this article
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
5